Menu
Back to Journals » Cancer Management and Research » Volume 4
Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
Received 6 May 2012
Accepted for publication 20 June 2012
Published 8 August 2012 Volume 2012:4 Pages 243—252
DOI https://doi.org/10.2147/CMAR.S25284
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Rosalie Fisher, James Larkin
Department of Medical Oncology, Royal Marsden Hospital, London, United Kingdom
Abstract: The BRAF inhibitor, vemurafenib, has demonstrated improved progression-free and overall survival compared with chemotherapy in a randomized trial, and represents a new standard of care in patients with advanced melanoma harboring a BRAF-V600 mutation. A BRAF-V600 mutation is identified in approximately half of patients with cutaneous melanoma, and is unequivocally a biomarker predictive of profound clinical benefit for these patients. However, acquired vemurafenib resistance is a major clinical challenge and therapy is not yet curative. A substantial body of translational research has been performed alongside clinical trials of vemurafenib, providing key insights into the molecular basis of response and resistance. This review summarizes the development of vemurafenib for the treatment of BRAF-V600 mutant melanoma and discusses how knowledge of critical signaling pathways will be applied for its optimal clinical use in future.
Keywords: vemurafenib, melanoma, BRAF-V600, BRIM-3
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.